Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir
Marie‐Noëlle Brunelle, Anne‐Carole Jacquard, Christian Pichoud, David Durantel, Sandra Carrouée‐Durantel, Jean‐Pierre Villeneuve, Christian Trépo, Fabien Zoulim – 24 May 2005 – Mutations within the hepatitis B virus (HBV) polymerase gene conferring drug‐resistance are selected during prolonged lamivudine (3TC) or adefovir dipivoxil (ADV) treatment. Because there is no other approved drug against HBV, treatments with 3TC or ADV are used either sequentially or in addition, depending on treatment response or failure.